Customizing the Targeting of IGF-1 Receptor

Overview

Journal Future Oncol

Specialty Oncology

Date 2009 Feb 27

PMID 19243297

Citations 19

Authors

Renato Baserga

Affiliations

Soon will be listed here.

Abstract

The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clinical trials. Targeting of the IGF-IR in cancer cells (by antibodies or other means) can be improved by the appropriate selection of responsive tumors. This review focuses on the optimization of IGF-IR targeting in human cancer.

Citing Articles

New insights into the prognosis of intraocular malignancy: Interventions for association mechanisms between cancer and diabetes.

Gu L, Ma G, Li C, Lin J, Zhao G Front Oncol. 2022; 12:958170.

PMID: 36003786 PMC: 9393514. DOI: 10.3389/fonc.2022.958170.

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.

Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J Neoplasia. 2018; 20(7):678-686.

PMID: 29842993 PMC: 6030389. DOI: 10.1016/j.neo.2018.05.004.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martinez-Cardus A, Marin-Aguilera M Br J Cancer. 2017; 117(12):1777-1786.

PMID: 29123263 PMC: 5729466. DOI: 10.1038/bjc.2017.279.

Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein.

Warsito D, Lin Y, Gnirck A, Sehat B, Larsson O Oncotarget. 2016; 7(27):42288-42302.

PMID: 27275536 PMC: 5173135. DOI: 10.18632/oncotarget.9785.

Analysis of cytosine-adenine repeats in P1 promoter region of IGF-1 gene in peripheral blood cells and cervical tissue samples of females with cervical intraepithelial lesions and squamous cervical cancer.

Kwasniewski W, Gozdzicka-Jozefiak A, Kotarska M, Polak G, Barczynski B, Broniarczyk J Mol Med Rep. 2014; 11(2):766-74.

PMID: 25384883 PMC: 4262512. DOI: 10.3892/mmr.2014.2916.